Hbk Investments L P Supernus Pharmaceuticals, Inc. Transaction History

Hbk Investments L P

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $1.41 Million - $1.81 Million	43,100 Added 169.02%	68,600 $2.4 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $260,813 - $418,706	8,457 Added 49.62%	25,500 $847,000
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $422,858 - $560,014	-9,903 Reduced 36.75%	17,043 $858,000
Q2 2018 Aug 14, 2018	SELL	$44.1 - $59.85 $1.27 Million - $1.72 Million	-28,770 Reduced 51.64%	26,946 $1.61 Million
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $624,714 - $788,670	16,816 Added 43.23%	55,716 $2.55 Million
Q4 2017 Feb 14, 2018	BUY	$36.4 - $42.6 $1.42 Million - $1.66 Million	38,900	38,900 $1.55 Million

283

60.6M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.11B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Hbk Investments L P, based on Form 13F filings with the SEC.

Stay updated on Hbk Investments L P with notifications on news.